Last reviewed · How we verify
NCT07191691: DEVMOTSUD
Observational Study of Psychomotor Development in Children Born in France to Parents Born in Sub-Saharan Africa.
trial testing Bayley Scales of Infant and toddler Development, fourth edition (BSID-4) in Psychomotor Performance in 240 participants. Not yet recruiting.
30 September 2027
Quick facts
| Lead sponsor | Etablissement Public de Santé Barthélemy Durand |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 240 |
| Start date | 6 October 2025 |
| Primary completion | 30 September 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Bayley Scales of Infant and toddler Development, fourth edition (BSID-4)
Conditions studied
- Psychomotor Performance — all drugs for Psychomotor Performance →
- Child Development — all drugs for Child Development →
- Culture — all drugs for Culture →
Sponsor
Etablissement Public de Santé Barthélemy Durand — full company profile →
Who can join
Adults 16 Days to 24 Months, any sex, with Psychomotor Performance or Child Development. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to determine whether there are specific characteristics of psychomotor development in children born in France to parents born in Sub-Saharan Africa, using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4). The main question it aims to answer : Is there a difference in the average raw scores on the motor scale between children born in France to parents from Sub-Saharan Africa and the French standard of the Bayley-4? Child participants will be included in the study, and their parents will complete a socio-demographic questionnaire. The children will then be observed by the investigator in an enriched environment for 60 to 90 minutes. If necessary, the investigator may provide verbal stimulation. The children will not be physically manipulated by the investigator, and breaks may be taken at any time as needed. Once the observation is complete, the participant's involvement in the study will end.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07191691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Etablissement Public de Santé Barthélemy Durand trials
Trials by the same sponsor.
- NCT05586672 — HR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD · not yet recruiting
- NCT05583240 — Influence of Olfaction Essential Oils on the Consumption of Benzodiazepine Receptor Agonists & Z-Drugs (BZRAs) Prescribe · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07191691 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Etablissement Public de Santé Barthélemy Durand
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07191691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing